Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a
human-relevant platform for cardiac function assessment. Alternative assays using hiPSC …

Given that cardiovascular safety concerns remain the leading cause of drug attrition at the
preclinical drug development stage, the National Center for Toxicological Research of the …

Cardiotoxicity has historically been a major cause of drug removal from the pharmaceutical
market. Several chemotherapeutic compounds have been noted for their propensities to …

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially
available, and cardiac differentiation established routine. Systematic evaluation of several …

Human pluripotent stem cell (hPSC)-derived cardiomyocytes provide a promising
regenerative cell therapy for cardiovascular patients and an important model system to …

The differentiation of pluripotent stem cells (PSCs) into diverse functional cell types provides
a promising solution to support drug discovery, disease modeling, and regenerative …

Human stem cell-derived cardiomyocytes (hSC-CMs) hold great promise as in vitro models
to study the electrophysiological effects of novel drug candidates on human ventricular …

Human-induced pluripotent stem cells (hiPSCs) are reprogrammed cells that have hallmarks
similar to embryonic stem cells including the capacity of self-renewal and differentiation into …

Contractility of the myocardium engines the pumping function of the heart and is enabled by
the collective contractile activity of its muscle cells: cardiomyocytes. The effects of drugs on …

In vitro reconstruction of highly mature engineered heart tissues (EHTs) is attempted for the
selection of cardiotoxic drugs suitable for individual patients before administration …